Plain-English, evidence-graded education on peptide therapy, compounded medications, GLP-1s, and the regulatory landscape — written for patients who want to understand the science before they start a protocol.
Latest articles
Recent posts from the blog.
Articles are written for an informed general audience — patients, clinicians, and anyone who wants to navigate the peptide therapy space with accurate information rather than hype.
Health OptimizationMetabolic HealthEducation
The New Health Stack: Why Context Beats Guessing
·7 min read
Health optimization is moving from chasing the next compound or hack toward connected decision-making. This piece explains the layered "health stack" — sleep, glucose, labs, wearables, and history — and why each signal is most useful in clinician-led context.
What Is Tesamorelin? FDA-Approved Use, Evidence, and Safety
·7 min read
Tesamorelin is the only FDA-approved GH secretagogue, but its approval is narrow. This guide separates the approved HIV-associated lipodystrophy indication from broader wellness claims and reviews the Phase 3 visceral-fat data, safety screening, and WADA status.
What Is Sermorelin? Evidence, Safety, and Regulatory Status
·7 min read
Sermorelin has a real GHRH mechanism and pediatric clinical history, but adult wellness claims still need careful evidence grading. This guide separates GH/IGF-1 biology from outcomes.
What Is TB-500? Evidence, Safety, and Regulatory Status
·7 min read
TB-500 is one of the most discussed recovery peptides online. This guide separates thymosin beta-4 repair biology, limited systemic human evidence, WADA status, and the July 2026 FDA review.
BPC-157 is one of the most discussed recovery peptides online. This guide separates what preclinical research suggests, what early human safety data can and cannot tell us, and why FDA compounding status matters in 2026.
Compounded vs Brand GLP-1s in 2026: A Plain-English Guide
·10 min read
The post-shortage landscape for GLP-1 medications changed fundamentally in early 2025. This plain-English guide explains the full regulatory timeline, when compounded semaglutide and tirzepatide are still legal in 2026, when they are not, and how to evaluate your options with your clinician.
Patients exploring peptide therapy face a false binary: unregulated grey-market peptides on one end, thousand-dollar-a-month brand drugs on the other. The middle path — licensed clinician oversight, 503A-compliant compounding, and evidence-based protocols — is what appropriate care actually looks like.
We don't have an email newsletter yet — but you can follow new articles through the RSS feed. Add https://yourhealthrx.us/blog/feed.xml to any RSS reader (Feedly, NetNewsWire, Reeder, etc.) to get new posts as they publish. We publish when there's something worth saying — not on an arbitrary schedule.
Ready to go further?
Discuss what you've read with a licensed clinician.
Education is the starting point. If you're considering a peptide protocol, a licensed clinician in our network can evaluate your history and determine what's clinically appropriate for you — anywhere in the US.